Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers
J Cortes, K Tamura, DJ DeAngelo, J De Bono… - British journal of …, 2018 - nature.com
Abstract Background Proviral integration Moloney virus (PIM) kinases (PIM1, 2 and 3) are
overexpressed in several tumour types and contribute to oncogenesis. AZD1208 is a potent
ATP-competitive PIM kinase inhibitor investigated in patients with recurrent or refractory
acute myeloid leukaemia (AML) or advanced solid tumours. Methods Two dose-escalation
studies were performed to evaluate the safety and tolerability, and to define the maximum
tolerated dose (MTD), of AZD1208 in AML and solid tumours. Secondary objectives were to …
overexpressed in several tumour types and contribute to oncogenesis. AZD1208 is a potent
ATP-competitive PIM kinase inhibitor investigated in patients with recurrent or refractory
acute myeloid leukaemia (AML) or advanced solid tumours. Methods Two dose-escalation
studies were performed to evaluate the safety and tolerability, and to define the maximum
tolerated dose (MTD), of AZD1208 in AML and solid tumours. Secondary objectives were to …
Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers
GL Uy - 2018 - digitalcommons.wustl.edu
BACKGROUND: Proviral integration Moloney virus (PIM) kinases (PIM1, 2 and 3) are
overexpressed in several tumour types and contribute to oncogenesis. AZD1208 is a potent
ATP-competitive PIM kinase inhibitor investigated in patients with recurrent or refractory
acute myeloid leukaemia (AML) or advanced solid tumours. METHODS: Two dose-
escalation studies were performed to evaluate the safety and tolerability, and to define the
maximum tolerated dose (MTD), of AZD1208 in AML and solid tumours. Secondary …
overexpressed in several tumour types and contribute to oncogenesis. AZD1208 is a potent
ATP-competitive PIM kinase inhibitor investigated in patients with recurrent or refractory
acute myeloid leukaemia (AML) or advanced solid tumours. METHODS: Two dose-
escalation studies were performed to evaluate the safety and tolerability, and to define the
maximum tolerated dose (MTD), of AZD1208 in AML and solid tumours. Secondary …
以上显示的是最相近的搜索结果。 查看全部搜索结果